Birmingham, United States
BioGX is a global molecular diagnostics company that has made significant contributions to the health and safety of communities worldwide since its establishment in 2007. Initially focusing on tests for Water Quality, Food Safety, and Pharma Quality Control, the company has evolved into a leading player in the molecular diagnostics industry. Headquartered in Alabama, USA, BioGX specializes in manufacturing custom-designed, platform-agnostic Sample-Ready™ reagents for Laboratory Developed Tests (LDTs) in the USA. Employing real-time PCR, the company's novel Sample-Ready™ approach simplifies molecular testing for labs by providing a high-performance mix of all necessary reagents, primers, and probes in a single tube, devoid of refrigeration needs. The technology extends across clinical, food safety, pharma, and water quality testing.
A wholly owned subsidiary, BioGX BV, based in Amsterdam, The Netherlands, offers a diverse portfolio of CE-IVD marked tests for various infectious diseases and operates globally through the Global Partnership Initiative. Notably, BioGX's products are used in outer space on the International Space Station, demonstrating the adaptability and high performance of their reagents. The company's commitment to continuous innovation and technological advancement aims to simplify, strengthen, and enhance RT-PCR for laboratories worldwide.
BioGX's strong presence in the biotechnology and manufacturing industries underscores its potential for expansion, innovation, and market competitiveness. While specific information about the last investment and investors is not available, the company's trajectory suggests promising opportunities for growth and global impact. BioGX's expertise, dedication to innovation, and wide-ranging applications position it as a compelling investment prospect in the rapidly evolving molecular diagnostics landscape.
